A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)
Status:
Terminated
Trial end date:
2011-07-12
Target enrollment:
Participant gender:
Summary
This is a Phase III, randomized, double blind, placebo-controlled, multicenter,
parallel-group study to evaluate the efficacy and safety of ocrelizumab compared to placebo
when combined with a single stable background immunosuppressive medication and a
corticosteroid regimen in patients with moderately to severely active systemic lupus
erythematosus, who do not have moderate to severe glomerulonephritis.